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Regulators of G protein signaling accelerate GTP
hydrolysis by Ga subunits and profoundly inhibit
signaling by G protein-coupled receptors. The dis-
tinct expression patterns and pathophysiologic
regulation of regulators of G protein signaling pro-
teins suggest that inhibitors may have therapeutic
potential. We previously reported the design,
mechanistic evaluation, and structure–activity
relationships of a disulfide-containing cyclic pep-
tide inhibitor of RGS4, YJ34 (Ac-Val-Lys-c[Cys-Thr-
Gly-Ile-Cys]-Glu-NH2, S-S) (Roof et al., Chem Biol
Drug Des, 67, 2006, 266). Using a focused one-
bead, one-compound peptide library that contains
features known to be necessary for the activity of
YJ34, we now identify peptides that bind to RGS4.
Six peptides showed confirmed binding to RGS4
by flow cytometry. Two analogs of peptide 2 (Gly-
Thr-c[Cys-Phe-Gly-Thr-Cys]-Trp-NH2, S-S with a
free or acetylated N-terminus) inhibited RGS4-
stimulated Gao GTPase activity at 25–50 lM. They
selectively inhibit RGS4 but not RGS7, RGS16, and
RGS19. Their inhibition of RGS4 does not depend
on cysteine-modification of RGS4, as they do not
lose activity when all cysteines are removed from
RGS4. Peptide 2 has been modeled to fit in the
same binding pocket predicted for YJ34 but in the
reverse orientation.
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Regulators of G Protein Signaling (RGS) proteins are GTPase accel-
erating proteins (GAPs) for Ga subunits (1). They diminish G protein-
coupled receptor (GPCR) signaling by binding to the activated Ga
protein and stabilizing the transition state for GTP hydrolysis (2).
Because RGS proteins have Ga specificity (1), receptor specificity
(3–6), and unique expression patterns (7), it has been suggested
that RGS inhibitors could selectively potentiate GPCR signaling in
specific tissues or brain regions (8–10). Others have suggested that
RGS inhibitors would be useful treatments for hypertension (11),
Parkinson's Disease (12), pain (13), cocaine reward (14), asthma
(15), diabetes (16,17), and cancer (18,19).
There have been over 30 RGS proteins identified (20), which are
divided into eight families (RZ, R4, R7, R12, RA, GEF, GRK, and
SNX families) based on the homology of the 120 amino acid RGS
domain as well as the presence or absence of other domains (1).
The R4 family contains the RGS domain as well as an amphi-
pathic N-terminus (21,22) that plays a role in membrane targeting
and ⁄ or receptor specificity (21–23). RGS4 is the prototypical mem-
ber of the R4 family. It has roles in cardiovascular and central
nervous system signaling and was the starting point for our RGS
inhibition efforts.
We previously reported the first RGS inhibitor, YJ34 (Ac-Val-Lys-
c[Cys-Thr-Gly-Ile-Cys]-Glu-NH2, S-S) (24). This peptide was designed
to mimic the switch 1 region of the Ga subunit and was modeled
from the RGS4-Gai1 crystal structure (25). It has a sequence similar
to the switch 1 region with two amino acid substitutions (Thr181 to
Cys and Val185 to Cys) to incorporate a disulfide bridge, which con-
strains the peptide in the correct conformation (24,26). This peptide
has an IC50 of 26 lM in a membrane-based steady state GTPase
assay (24), a 9 lM IC50 in a purified protein single turnover GTPase
assay (26), inhibits RGS4 81% at 40 lM in a capillary electrophore-
sis assay (27), and an analog inhibits RGS modulation of G-protein
inwardly rectifying potassium current kinetics in atrial myocytes
(26). It has been found that BR2 (Ac-Val-Lys-c[Cys-Thr-Ser-Ile-Cys]-
Glu-NH2, S-S), a peptide that mimics the RGS-insensitive G184S
mutation in the Ga protein, is inactive, suggesting that YJ34 binds
to RGS4 as designed (i.e., in the same way that the Ga switch 1
binds). Structure–activity relationship studies on this peptide
111
Chem Biol Drug Des 2008; 72: 111–119
Research Article
ª 2008 The Authors
Journal compilation ª 2008 Blackwell Munksgaard
doi: 10.1111/j.1747-0285.2008.00687.x
showed that the following features were necessary for peptide
activity: the N-terminal acetyl group, C-terminal amide, the Gly at
position 5, and Cys residues at positions 3 and 7 linked by a disul-
fide bridge (26).
Peptide YJ34 is a useful tool for studying RGS function, but we
wanted to find other, hopefully more potent, RGS inhibitors. We
report here the use of a focused one-bead, one-compound (OBOC)
(28) peptide library to screen for RGS4 inhibitors. The library was
restricted to contain peptides with the features mentioned above
that are required for the function of YJ34. The other five amino
acids were randomized among the 19 natural amino acids (except
Cys) to afford 2.5 million possible peptide sequences. The library
was synthesized and screened for RGS4 binding using beads con-
taining only one peptide sequence each. Half of the peptides on
each bead had an acetyl group, because it is important for peptide
YJ34 function, while half had a free N-terminus, to allow
sequencing by Edman degradation. From this screen, we identified
seven peptide sequences that bound RGS4. Two analogs of peptide
2, 2ad (Ac-Gly-Thr-c[Cys-Phe-Gly-Thr-Cys]-Trp-NH2, S-S) and 2nd




Fmoc-protected amino acids and Rink amide resin were purchased
from Advanced ChemTech (Louisville, KY, USA). Fmoc protected and
acetylated amino acid purity was verified by high performance
liquid chromatography (HPLC). Tentagel Resin was purchased from
ChemImpex (Wood Dale, IL, USA) or Rapp-Polymer (Tubingen, Ger-
many), and Alexa Fluor label from Invitrogen (Carlsbad, CA, USA).
Peptide synthesis grade chemicals were purchased from either
Applied Biosystems (Foster City, CA, USA) or Sigma-Aldrich (St
Louis, MO, USA). c[32P]GTP (10 mCi ⁄ mL) was purchased from Perkin
Elmer (Boston, MA, USA) and diluted with unlabeled GTP to the
desired level of radioactivity. Amylose resin was purchased from
New England Biolabs and the Ni-NTA resin from Qiagen.
Protein expression, purification, and labeling
His6-Gao (rat) and RGS4D18N (rat), were expressed and purified
according to previous protocols (29–32). Mbp-His6-RGS4D51N
(human), Mbp-His6-RGS16 (human), Mbp-His6-RGS19D11C (human),
Mbp-His6-RGS7 RGS domain (human, nucleotides 915–1359), and
the mutant Mbp-His6-RGS4D51N lacking all seven cysteines
(called '-7C') were in Gateway pMAL vectors and were expressed
using a similar protocol as the RGS4D18 construct and purified over
an amylose column followed by an Ni-NTA column according to the
manufacturer's protocol. In some cases, this was followed by a size
exclusion column as necessary. The mutagenesis was carried out
using the 'QuickChange Multi Site-Directed Mutagenesis Kit' from
Stratagene according to the manufacturer's protocol. Labeling of
RGS4 with succinimide ester fluorophores (Alexa Fluor 568 and
Alexa Fluor 532) was performed according to the manufacturer's
protocol using approximately twofold to threefold excess
fluorophore.
OBOC peptide library synthesis
The protocol was based on previous reports (28,33) using a man-
ual 'mix and split' synthesis. TentaGel amide resin (10 g of
130 lm-sized beads with a substitution level of 300 pmol) was
swelled in N-methylpyrrolidone (NMP) and divided by volume into
19, 8.0-mL polypropylene filter columns (Alltech, Deerfield, IL,
USA). To each column, a solution of a different Fmoc-protected
amino acid in NMP was added; all natural amino acids were
used except cysteine. This was followed by a solution containing
a threefold excess 2-(1H-Benzotriazole-1-yl)-1,1,3,3,-tetramethyl-
aminium hexafluorophosphate ⁄ 1-hydroxybenzotria-zole (HBTU ⁄ HOBt)
and 2 M N,N¢-diisopropylethylamine (DIEA) in NMP and the mix-
ture was shaken for 1 h at room temperature. Then the beads
were rinsed thoroughly with NMP. Unreacted amino groups on
the resin were acetylated with a 20-fold excess of acetic anhy-
dride with DIEA and HOBt in NMP. After a negative bromophenol
blue test for free amines, the beads were pooled and treated
with 50% piperidine in NMP. The splitting, coupling, pooling, and
deprotection (but not the acetylation) steps were repeated for
the randomized positions. For the non-random positions, the resin
was not split and Fmoc-Cys(trt)-OH (position 3 or 7) or Fmoc-Gly-
OH (position 5) was coupled to the whole batch of beads. In
the final coupling step, a 1:1 mixture of acetylated and Fmoc-
protected amino acids was used. To remove the side chain pro-
tecting groups without cleaving the peptide from the resin (33),
all the beads were pooled and treated with 50 mL ice-cold
88:5:5:2 trifluoroacetic acid (TFA):phenol:water:triisopropylsilane
(TIPS) and shaken for 3 h at room temperature. Treatment of test
peptides with deprotection reagents resulted in no detectable
cleaved peptide as checked by HPLC. After thorough washing
(including a wash in 10% DIEA to neutralize obtained TFA salts),
the resin was added to 7.8-L oxidation solution [20% Dimethyl-
sulfoxide (DMSO), 5% Acetic acid, in water pH 6.0 purged of air
with N2] and shaken for 48 h.
Library screening
Beads were washed and plated in a single layer (on an average,
approximately 1500 beads per well) in 96-well plates in buffer
(1% BSA in 20 mM Hepes pH 8.0) and incubated with 25 nM
RGS4D18N-Alexa Fluor 568. Wells containing beads with YJ34
were included in every scan as a control. Fluorescence was
imaged on a Typhoon 9200 Gel Imager using an excitation of
532 nm and an emission of 610 nm and the fluorescence was
quantified with the accompanying ImageQuant software. To do
this, a 12 · 8 grid was placed over the image such that each
grid block contained only one well. Grid blocks that contained an
object with intensity more than 5- to 10-fold over the most
intense object in the wells containing YJ34 were collected and
pooled. The image was visually inspected and any objects that
were clearly not beads, such as dust or other debris, were
excluded. Pooled beads were washed with buffer, diluted, and re-
screened against 10 nM RGS4D18N-Alexa Fluor 568. The process
was repeated with lower RGS4 concentrations until a single bead
per well was obtained. The top 20 hits were then isolated with a
needle under a dissecting microscope and sent for sequencing by
Edman degradation at the Biomedical Research Core Facilities at
the University of Michigan.
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Synthesis of individual peptides
Soluble (not bead-bound) peptides (for GAP assays) were synthe-
sized on Rink resin, cleaved from the resin and cyclized as
described previously (24,26). Peptide purity (at least 95%) and sol-
ubility were verified by HPLC and correct mass was verified by
mass spectrometry analysis (26). YJ34 and BR2 bead-bound con-
trols were synthesized on 130 lm Tentagel resin using the same
protocol as the library except that no 'mix and split' steps were
incorporated. Hit peptides on beads (for the FACScan assays) were
synthesized on 20 lm Tentagel resin using a LabMate apparatus
(Advanced ChemTech) and cyclized manually using the similar
chemistries as for the library with no 'mix and split' randomization.
The deprotection mixture was 83:5:5:5:2 TFA:thioanisole:phe-
nol:TIPS and an Ellman test was performed to ensure complete
oxidation.
Binding of test peptides
Unreacted 130 lm TentaGel amide resin, or resin containing YJ34
or BR2 was put into wells of a 96-well plate with 5 mg per well
in 0.5 mL buffer (1% BSA in 20 mM Hepes pH 8.0) for 1 h. The
supernatant was removed and various concentrations of Alexa Fluor
568 labeled RGS4D18N were added in 200 lL followed by incuba-
tion for 15 min. After a wash with 500 lL buffer, fluorescence was
measured in black Costar 96-well plates in a Victor2 fluorescence
plate reader with an excitation filter at 560 and an emissions filter
at 595. Samples were measured in duplicate.
FACScan flow cytometry
Peptide beads (about 5 · 103 per sample for a maximum of 5 nmol
peptide) were washed and then incubated with 25 nM RGS4D51N-
Alexa Fluor 532 in 300 lL for at least 15 min at room temperature
under foil. The Becton Dickinson FACScan was gated and the laser
intensity set in CellQuest such that control beads (acetylated Tenta-
Gel resin) were gated and had low but measurable fluorescence.
No compensation was set. Fluorescence of RGS4D51N-Alexa Fluor
532 bound to acetylated beads (about 60% of YJ34 beads) was
considered background and subtracted from all samples. Samples
were read in duplicate.
RGS-stimulated GTPase
Single turnover GTP hydrolysis measurements with and without
RGS were performed as described previously (26).
Modeling
Peptides were modeled using Quanta (Accelrys Inc., San Diego, CA,
USA) by modifying the residues from the Gai1 switch 1 in the
RGS4-Gai1 (PDB entry: 1agr) crystal structure (25). Upon residue
substitution and formation of the disulfide bond, energy minimiza-
tion of each peptide with all hydrogen atoms added was performed
using the QUANTA ⁄ CHARMM simulation package (Accelrys) with dielec-
tric constant () = 10 and the Adopted-Basis Newton Raphson
method (50 steps). To model the peptide–RGS complex, each mini-
mized peptide with the hydrogens removed was substituted for the
corresponding Gai fragment from the Gai-RGS4 complex. Images
were prepared using PyMol for OS X (http://www.pymol.org).
Statistical analysis
Data are expressed as mean € SEM (or € SD for n = 2) and ana-
lyzed by either a t-test (GAP data) or a one-way ANOVA (Victor-based
test binding and FACScan data). A Bonferroni post-test was carried
out on the FACScan data. Significance is indicated as follows:
*p < 0.05, **p < 0.01, ***p < 0.001.
Results and Discussion
OBOC library design and screening
It has been found previously that several structural features were
necessary for activity of YJ34: the N-terminal acetyl group, the
C-terminal amide, Gly at position 5, and Cys at positions 3 and 7
with their side chains linked via a disulfide bridge. However, the
other five positions can be varied (26). As seen in Table 1, the fea-
tures necessary for YJ34 function were constrained in the library,
while the other positions were randomized. All natural amino acids
except Cys were used in the other five positions to give 2.5 million
possible sequences. Using 10 g of 130 lm TentaGel beads provides
approximately 7.9 million beads; thus each sequence would have
Table 1: OBOC library design
The key features of YJ34 were constrained in the library. The library had the Gly at position 5, the Cys at posi-
tions 3 and 7 with a disulfide bonds, and a C-terminal amide. The other five amino acid positions were random-
ized such that each bead had only one sequence. Half of the peptides on each bead had an acetyl group and
the other half had a free N-terminus. There were 300 pmol peptide on each bead, 2.5 million sequences, and 7.9
million beads in the library.
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been present on three beads in the library, on an average. In an
OBOC library, each bead has only one amino acid sequence. How-
ever, for this library, half of the peptides on each bead were acety-
lated, as this is necessary for the function of YJ34, and half had
a free N-terminus, to allow sequencing by Edman degradation. The
beads had a substitution level of 300 pmol per bead, resulting in
about 150 pmol of free-amine-containing peptides for sequencing.
This was found to be sufficient for sequencing of test peptides
(data not shown). In addition, as a control, we ensured that YJ34
on beads bound to RGS4 (Figure 1). Although TentaGel resin is
known not to be cleavable with TFA treatment (33), it was verified
that deprotection conditions did not remove test peptides from resin
(see Methods). Tentagel resin was chosen because it has been
used extensively and has good mechanical stability and has a uni-
form size. Unfortunately, it has green autofluorescence (34), and so
a red dye (Alexa Fluor 568) was chosen for RGS4 labeling for the
library screen. Others have found non-specific binding to be prob-
lematic with this resin (Anna Mapp, personal communication, 2008).
We did find high non-specific binding to unreacted resin (data not
shown), but this was not observed with acetylated resin or with
resin containing BR2 [Ac-Val-Lys-c[Cys-Thr-Ser-Ile-Cys]-Glu-NH2,
S-S, which is an inactive peptide that mimics the RGS insensitive
mutation in the Ga protein (26)].
To screen the library, the beads were incubated with Alexa Fluor
568 labeled RGS4D18N and imaged in a Typhoon Gel Imager as
shown in Figure 2. The top 20 most fluorescent beads were iso-
lated and sequenced by Edman degradation. Unfortunately, six of
the hits yielded only partial sequences, leaving 14 fully sequenced
hits for further evaluation.
Hit verification
Each of the 14 sequenced hit peptides was resynthesized on
20 lm TentaGel beads. As both were present in the library, free
N-terminal, disulfide bridged (nd) and acetylated, disulfide bridged
(ad) versions of each sequence were synthesized. Interaction with
Alexa Fluor 532 labeled RGS4D51N was detected in a FACScan
Flow Cytometer (Figure 3). The RGS4D51N protein lacking the
amphipathic helix in the N-terminus was used to ensure that the
verified hits bound to the RGS domain of RGS4. Using 2.5-fold
increased binding of RGS4D51N-Alexa Fluor 532 compared with
YJ34 on beads as a cut-off, it was found that some of the ini-
tial hits were false positives, but peptides 1, 2, 3, 4, 7, 11, and
14 (Figure 3, Table 2) were verified and were chosen for further
evaluation. The hits were structurally divergent from our lead
compound. Both the free N-terminal and the acetylated versions
of the verified hits bound RGS4D51N. This is in contrast to
YJ34, where only the acetylated version has activity in the GAP
assay (26).
Figure 1: Alexa Fluor 568 labeled RGS4D18N binds peptide
YJ34 (filled bars) on beads but not peptide BR2 (open bars) on
beads. Binding of RGS4 to beads was measured as described. The
experiment was carried out in duplicate (mean € SD, n = 2).
*p < 0.05, **p < 0.01, ***p < 0.001 compared with no RGS4D18N-
Alexa Fluor 568.
Figure 2: Screening of the
library. The library was screened
for binding of RGS4 as described.
The left two wells contain peptide
YJ34 on beads while the right
four wells contain library beads.
Fluorescence was quantified and
represented by the number below
the circled beads.
Roof et al.
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Peptide activity in GAP assays
Peptides were tested at 50 lM except for YJ34, 2ad, and 14nd,
which were limited by solubility. Effects on the rate of RGS-stimu-
lated Gao GTPase activity were measured in a single turnover
assay with purified proteins and peptides in solution (Figure 4). Hit
11 was not evaluated because of signs of aggregation. Only pep-
tides 2nd (the free N-terminal, disulfide bridged hit 2) and 2ad
(the acetylated, disulfide bridged peptide 2) had statistically signifi-
cant inhibition of RGS4 activity (48 € 7% inhibition at 50 lM and
30 € 12% inhibition at 25 lM, respectively). Based on these values,
both peptides have an estimated IC50 of about 50 lM. Other pep-
tides that had some activity included 1nd (33 € 15% inhibition at
50 lM) and 4nd (33 € 16% inhibition at 50 lM, Figure 4). The
activity of hit 2 was investigated further in Figure 5. Linear as well
as disulfide bridged versions of peptide 2 (2nl: free N-terminal lin-
ear and 2al: acetylated linear) were tested in the GAP assay, as
cyclization yields may have been less than 100% in the synthesis
of the library leaving some linear peptides present on each bead,
which may have contributed to the observed fluorescence of the
bead (Figure 5A). Consistent with previous results for YJ34, the
linear peptides were inactive. Regulators of G protein signaling
selectivity was also investigated. Interestingly, peptides 2ad and
2nd were inactive against RGS7, RGS16, and RGS19 (Figure 5B).
The RGS16, like RGS4, is in the R4 family, while RGS7 and RGS19
are in different families (R7 and RZ, respectively) and have lower
homology with RGS4.
Recently, CCG-4986, a small molecule inhibitor of RGS4 was identi-
fied and found to interact with RGS4 through cysteine modification
[(32,35), David Roman, unpublished observation]. For this reason,
the activity of our original peptide, YJ34, as well as that of hit 2
was evaluated with an RGS4D51N mutant lacking all seven cyste-
ines (-7C) (Figure 5C). The -7C mutant was inhibited by 2ad, 2nd,
and YJ34. There was no statistically significant difference
between the activity on wild type and the -7C RGS4D51N for 2ad,
2nd or YJ34 (59 € 4%, 27 € 7%, 60 € 11% inhibition for 2ad,
2nd, and YJ34, respectively). This indicates that hit 2 does not
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Figure 3: Hit verification. The 14 hits for which complete sequences were obtained were resynthesized on beads and tested for binding
to RGS4D51N-Alexa Fluor 532 as described [mean € SEM (or SD where n = 2), n ‡ 2]. Acetylated peptides are the filled bars and the free
N-terminal peptides are in the open bars. *p < 0.05, **p < 0.01, ***p < 0.001 compared with YJ34 on beads.









Peptides from Figure 3 that bind RGS4D51N-Alexa Fluor 532 at least 2.5-
fold more than YJ34 are shown. Note that both acetylated, disulfide
bridged (ad) and free N-terminal, disulfide bridged (nd) peptides were cho-























































































































































































Figure 4: Activity of hit peptides in a single turnover GAP assay.
(A) Representative time course. (B) Rates were calculated based on
the time courses, and percent decrease in the rate of RGS-stimulated
GTP hydrolysis by peptides was measured (mean € SEM, n ‡ 3).
*p < 0.05, **p < 0.01, ***p < 0.001 compared with no peptide.
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Conclusions
Inhibition of protein–protein interactions (PPIs) is particularly chal-
lenging. Unlike enzymes and receptors that have well-defined
pockets, protein–protein interfaces tend to be large and flat (36).
Because of this, many PPIs have been declared 'non-amenable' to
inhibition by drug-like molecules based on computational measure-
ments (37). In fact, the RGS4-Gao interaction falls in this category
(David Fry, personal communication, 2006). However, some protein–
protein interfaces have been found to have 'hot spots', which are
a limited number of residues that are responsible for the majority
of the interaction energy. Others have taken advantage of this to
successfully create peptide and small molecule inhibitors of PPIs
(38–40). In addition, computational approaches such as those used
in Fry and Vassilev (37) are based on rigid crystal structures of
proteins. Others have shown that protein interfaces are adaptable
and in multiple cases, small molecules bind in induced pockets
that are not observed in the crystal structures of the protein alone
or in complex with its natural protein-binding partner [(41) and
references therein]. Thus, these interactions could not be rationally
predicted in spite of the existence of a structure of the target
protein and could only come from experimental screening. Hence,
although this was an ambitious project, there are ample prece-
dents for success. In fact, the above-mentioned small molecule
inhibitor of RGS4, CCG-4986, was found in a screen to block the
RGS4-Gao interaction (32). Inhibitors of RGS4 were also found in
a yeast-based screen, but unfortunately, no structures were
reported (42).
Of the seven RGS4-binding peptides found in our OBOC peptide
library screen, one peptide sequence (in both free amide and acety-
lated form) was found to inhibit RGS4 GAP activity in the single
turnover GAP assay. Although the potency of the new compounds is
no greater then the starting peptide, we have identified new pep-
tides that we believe have the desired mode of binding to RGS4,
and the desired RGS4 inhibitor activity.
Based on the crystal structure of RGS4 bound to Gai (25), Thr182 of
Gai forms hydrogen-bonding and hydrophobic interactions with sev-
eral residues in RGS4 including Asn88, Asp163, Ser164, and
Leu159. The corresponding residue in YJ34, Thr4, may similarly
interact with RGS4 residues. However, there is a Phe at this posi-
tion in peptide 2 and it is unlikely that this bulkier, non-polar side
chain interacts with RGS in the same manner as does the Thr4 side
chain of YJ34 (Figure 6A). However, if the peptide were rotated
around the central Gly (i.e., oriented as a retrobinder in the YJ34
binding site), then the Thr in position 6 would be placed into the
pocket where Thr182 of switch 1 binds and the Thr4 of YJ34 is
predicted to bind. This would also position the Phe4 of hit 2 above
Tyr84 in RGS4 where Ile185 from switch 1 is located. These two
amino acid interactions are reminiscent of a previously identified
YJ34 analog, [Ac-Val-Lys-[Cys-Thr-Gly-Phe-Cys]-Glu-NH2, S-S, pep-
tide 20 in Roof et al. (26)], which has a Thr at position 4 and a
Phe at position 6. This peptide inhibited RGS4 GAP activity by
nearly 40% at 100 lM (26). Thus, we propose that hit 2 interacts
with RGS4 in the switch 1 binding site in an inverse orientation





































































































































































































































































Figure 5: Functional activity of
peptide 2. (A) Disulfide-bridged
(2nd and 2ad), but not linear
(2nl and 2al) peptides inhibit
RGS4D51N GAP activity. (B) Pep-
tides 2nd and 2ad are selective
for RGS4D51N (75–125 nM) over
RGS7box (500 nM), RGS16 (1.5 lM)
or RGS19 (200 nM). (C) Activity of
2nd and 2ad on wild type and -
7C mutant (200 nM) RGS4
[mean € SEM, (or SD where
n = 2), n ‡ 2]. *p < 0.05,
**p < 0.01, ***p < 0.001 com-
pared with no peptide.
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favorable hydrophobic interactions with Leu159. On the contrary,
because of the inverse position of the peptide 2 in the binding site,
its N-terminus likely occupies a position of YJ34 C-terminus, while
C-terminal amide of peptide 2 is positioned similarly to
YJ34 N-terminus. The presence of positively charged Lys155 and
Lys162 of RGS4 near N-terminus of YJ34 may explain the poor
activity of its non-acetylated version. However, the proposed
different location of the peptide 2 N-terminus would not require its
acetylation.
Although it is believed that hit 2 binds the YJ34 binding site, it is
possible that some of the other peptides do not. In fact, the obser-
vation that many of them do not have an effect on GAP activity
would suggest that this may be the case and that these analogs
interact with RGS in alternate ways. This may explain why peptide
4, for example, bound RGS4 so well in the FACScan assay (Figure 3)
while having little effect on RGS4 GAP activity (Figure 4). The RGS4
has been shown to have an allosteric site where phosphatidylinosi-
tol-3,4,5-trisphosphate (PIP3) and calmodulin are known to bind (43).
Calmodulin binding alone does not affect GAP activity, but blocks
the inhibition by PIP3 (43). It is therefore possible that some of the
peptides isolated in the library bind RGS4 at this site without
affecting RGS4 GAP activity. Alternatively, these peptides may bind
other, perhaps as of yet unidentified, protein–protein interaction
sites. The fact that the sequences obtained in the library are so
divergent from the sequence of YJ34 also supports the possibility
that many of the hit peptides do not bind at the YJ34 binding
site. In fact, it is hard to find any clear structural clusters based on
the homology of the varied positions. It is therefore speculated that
RGS4 may have several peptide (and therefore endogenous protein
or lipid) binding sites.
As in the YJ34 series, linear versions of hit 2 are inactive. In
addition, as in the YJ34 series, hit 2 is most active on RGS4 com-
pared with RGS7. It is thought that CCG-4986 inhibits RGS4 through
cysteine modification [(32,35), David Roman, personal communica-
tion, 2008]. Because of the apparent sensitivity of RGS4 to cysteine
modifications, and because of cysteines in the peptides, it was
examined whether a similar mechanism might exist here. Hence,
peptides 2ad, 2nd, and YJ34 were tested against the -7Cys
RGS4D51N mutant. The observation that none of the peptides dif-
ferentiated between wild type and the -7C mutant supports a
mechanism of action like that of YJ34, rather than via a covalent
interaction with RGS4 cysteines.
The side chain order and ring size of 2ad and 2nd are the same
as in peptide 20 in Roof et al. (26) within the cycle; however, the
backbone is different. The fact that both have activity opens up the
possibility for non-peptide analogs such as b-amino acid and pep-
toid analogs. Peptidomimetics have the advantage of not being pro-
tease substrates and this increased stability makes them more
useful in cells and in vivo (44), making them an interesting avenue
for future investigations.
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